1 1 1 1 99 1 1 1 1 99
2 98 2 98 2 98
Risk Reduction Realized
TM
In NVAF patients vs warfarin … • Superior reduction of stroke / SE † 2 • Similar rates of major bleeding † 2
Specifi c reversal agent available nationwide * 1 For more information and to locate reversal near you ,
visit PRADAXAPRO . com
75
2
50
98
25
2
75K
75C , 63M , 63Y
50K
50C , 39M , 39Y
75
50
25
75 75
50 50
25
C + M 75 50 75
C + Y 75 50 50
98 2
M + Y 75 25 25
98 2 98 2 98
3 97 3 97 3 97 3 97 3 97 3 97 3 97 3 97
4 96 4 96 4 96 4 96 4 96 4 96 4 96 4 96
5 95 5 95 5 95 5 95 5 95 5 95 5 95 5 95
99.5 0.5 99.5 0.5 99.5 0.5 99.5 0.5
25 99 99 99
25
25
25
GATF / SWOP Digital Proofing Bar
300 %
80K , 80C , 70M , 70Y
99.5 0.5 99.5 0.5 99.5 0.5 99.5 0.5
75 75 C + M 75 50 25 99 99 99
50 50 C + Y 75 50 25
25 25 M + Y 75 50 25
25K
25C , 16M , 16Y
Please see Important Safety Information about PRADAXA on next page .
75
50
25
*Boehringer Ingelheim Pharmaceuticals ,, Inc .. cannot guarantee the availability of the reversal agent .. Institutions in each state have purchased the reversal agent .. †Event rates with PRADAXA vs warfarin in the RE-LY ® Trial :: 135 [ 2.2 %] vs 203 [ 3.4 %] stroke / SE events ,, HR :: 0.65 ,, 95 % CI [ 0.52 ,, 0.81 ], P = 0.0001 ;;
and 350 [ 3.5 %] vs 374 [ 3.6 %] major bleeding events ,, HR :: 0.97 ,, 95 % CI [ 0.84 ,, 1.12 ]; respectively .. 2 Rates of stroke / SE refl ect the % of patients with an event at fi fi rst occurrence in the RE-LY Trial ;; major bleeding events were calculated as % per 100 patient-years ..